Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07237607 · ClinicalTrials.gov registry record · NA

Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders

A NA study of Anorexia Nervosa and Binge-Eating Disorder, sponsored by Milton S. Hershey Medical Center.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT07237607: Recruiting NA study of Anorexia Nervosa and Binge-Eating Disorder, sponsored by Milton S. Hershey Medical Center.

NCT07237607 is a NA study of Anorexia Nervosa and Binge-Eating Disorder that is actively recruiting participants, run by Milton S. Hershey Medical Center. The registered enrollment target is 20 participants, below the 950-participant average among 43 other Anorexia Nervosa trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07237607, a NA study of Anorexia Nervosa and Binge-Eating Disorder, is actively recruiting participants, sponsored by Milton S. Hershey Medical Center.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to develop and refine an artificial intelligence (AI)-powered Exposure Therapy for Eating Disorders chatbot web-app that effectively engages adolescents and young adults and decreases anxiety about weight gain. Participants will use the web-app as a supplemental therapeutic tool during their first six weeks of treatment in a Partial Hospitalization Program. Participants will complete assessments every two weeks, including: (1) semi-structured interviews about their experience with the chatbot web-app; (2) implementation outcome measures (e.g., feasibility, usability, acceptability); and (3) anxiety about weight gain.

Primary Outcome

The investigators will measure the number of times participants use the web-app

Interventions

  • BEHAVIORAL "Exp-ED" Digital Exposure-Therapy Chatbot app

Study Locations (1)

Pennsylvania

  • Penn State College of Medicine - Hershey

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2026-03-02
Est. Completion 2027-06-30
Phase NA
Milton S. Hershey Medical Center

396 total trials

What NCT07237607 shows while recruiting

NCT07237607 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 950-participant average among 43 other Anorexia Nervosa trials with a reported enrollment target (98% lower).

The record links to 4 conditions, with Anorexia Nervosa appearing as the primary indexed condition, and to 1 intervention - of which "Exp-ED" Digital Exposure-Therapy Chatbot app is the first listed.

NCT07237607 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07237607 about?

NCT07237607 is a clinical study titled "Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders". The goal of this study is to develop and refine an artificial intelligence (AI)-powered Exposure Therapy for Eating Disorders chatbot web-app that effectively engages adolescents and young adults and decreases anxiety about weight gain. Participants will use the web-app as a supplemental therapeutic...

What is the current status of trial NCT07237607?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2026-03-02. Estimated completion is 2027-06-30.

What conditions does trial NCT07237607 study?

This clinical trial studies the following conditions: Anorexia Nervosa, Binge-Eating Disorder, Eating Disorders, Bulimia Nervosa.

What interventions are being tested in trial NCT07237607?

The interventions under investigation include: "Exp-ED" Digital Exposure-Therapy Chatbot app (BEHAVIORAL).

Who is sponsoring clinical trial NCT07237607?

This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07237607 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anorexia Nervosa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07237607's enrollment target sits among peer trials

20 35th of 43 higher than 5 of 43 other Anorexia Nervosa trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anorexia Nervosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07237607, the US trial registry maintained by the National Library of Medicine. NCT07237607 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.